Teva reiterates interest in Mylan; Caforio in as BMS chief; China to nix price caps;

@FiercePharma: India eases path for small companies to bid in medical product tenders. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI: Novo putting $225M into new plant in Denmark for hemophilia treatments. Report | Follow @EricPFierce

@CarlyHFierce: Big new launches rocket cancer drug spending to $100B: IMS report. More | Follow @CarlyHFierce

> Teva ($TEVA) has filed an updated investor presentation reiterating its $82-per-share Mylan ($MYL) buyout proposal. Release

> Giovanni Caforio has assumed the post of CEO at Bristol-Myers Squibb ($BMY). Report

> China will remove price caps for most therapies from June 1, and giving the market a larger role in setting prices in the country. More

> The Supreme Court has brought Bristol-Myers Squibb's hopes of reviving patent protection for its Baraclude hep B treatment to an end, declining to hear its challenge to an appeals court ruling in favor of copycat drugmaker Teva. Report

> Teva has closed its $3.2 billion acquisition of Auspex Pharmaceuticals. Report

> Mallinckrodt ($MNK) said its profit leapt in its latest quarter, and it lifted its outlook for the year after recent pickup Ikaria helped boost sales. Report

Medical Device News

@FierceMedDev: Myriad Genetics stumbles as rivals flood BRCA market. FierceDiagnostics story | Follow @FierceMedDev

@EmilyWFierce: Scientists harness new technology for artificial knee implants. Report | Follow @EmilyWFierce

> Open-source software released to connect Apple ResearchKit to the cloud for use in clinical trials. News

> Researchers question safety of off-label device use in atrial fibrillation, call for 510(k) review process. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Bayer fronting $155M for a promising anticoagulant from Isis Pharma. Report | Follow @FierceBiotech

@JohnCFierce: The drumbeat of bad news at $GSK should lead to a change of CEOs. Breaking up the co. will be the focus as well. More from Bloomberg | Follow @JohnCFierce

> Tobira pulls off a $40M Wall Street end-around with sights set on NASH. More

> Roche presses pause on PTC's SMA drug over a safety scare. Article

> Corbus who? A tiny biotech is shoved into the rink with a hulking Vertex. Story

> GlaxoSmithKline files for gene therapy OK as a case of the jitters sets in. Report

Pharma Manufacturing News

> Zoetis to whack 10 plants as part of cost-cutting scheme. News

> U.K. regulators find issues with Indian-owned API distributor Relonchem. More

> WuXi starts work in China on yet another cell-line manufacturing facility. Article

> Recro Pharma and Alkermes close deal on DEA-approved plant in Georgia. Story

> Novo building $225M plant for hemophilia treatments. Report

Pharma Asia News

> China's SAIC denies probe as reports proliferate on alleged devices crackdown. Article

> India eases path for small companies to bid in medical product tenders. Story

> China plans first-ever rules on animal testing in medical research by year end. More

> Otsuka device unit works with UniCare on urinary bladder products. Report

> Japan to adopt CDISC clinical data standards from October 2016. Item

Drug Delivery News

> NIH says viral vector for delivering gene therapy to treat blindness shows promise, Wall Street less sure. More

> UNC scientists bypass blood-brain barrier with exosomes to treat Parkinson's. Report

> Northwestern team puts spherical RNA in common skin moisturizer to speed up wound healing. Story

> Medicines Co. gets FDA approval of first patient-controlled patch for postoperative pain. Item

> Deerfield Management buys 8% stake in manufacturer of custom hydrogels and wound dressings. Article

And Finally... A drug derived from Caribbean reefs may treat psoriasis and multiple sclerosis. Story